会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Liquid crystalline polymers
    • 液晶聚合物
    • US06465002B1
    • 2002-10-15
    • US09523887
    • 2000-03-13
    • Edith MathiowitzJules S. JacobYong S. JongDonald E. Chickering, IIIEdwin E. Edwards
    • Edith MathiowitzJules S. JacobYong S. JongDonald E. Chickering, IIIEdwin E. Edwards
    • A61F1300
    • C09K19/38B29C55/00B29C55/18B29K2105/0079
    • Methods for inducing a thermoplastic polymer, which can be non-mesogenic, to exhibit liquid crystalline properties have been developed. The method includes the steps of (a) heating the polymer from an initial temperature below its glass transition temperature (Tg) to a temperature greater than its Tg and below its melting temperature (Tm); (b) exposing the polymer to a pressure greater than about 2 metric tons/in2, preferably between about 2 and 10 metric tons/in2, preferably for at least about one minute, while maintaining the temperature greater than its Tg; and (c) cooling the polymer below the Tg while maintaining the elevated pressure. Unlike many prior art transition processes which are reversible, this process provides a liquid crystal state that can be maintained for years at ambient conditions. In a preferred embodiment, the plastics are bioerodible thermoplastic polymers, such as polyanhydrides, some polyesters, polyamides, and polyaromatics. The liquid crystalline polymers can be used in the controlled release or retention of substances encapsulated in the polymers. The polymer can be in a variety of forms including films, film laminants, and microparticles. In a preferred embodiment, the LC polymers are used to encapsulate therapeutic, diagnostic, or prophylactic agents for use in medical or pharmaceutical applications.
    • 已经开发了用于诱导可以是非介晶的热塑性聚合物以显示液晶性质的方法。 该方法包括以下步骤:(a)将聚合物从低于其玻璃化转变温度(Tg)的初始温度加热至大于其Tg并低于其熔融温度(Tm)的温度; (b)将聚合物暴露于大于约2公吨/ in2的压力下,优选约2至10公吨/ in 2,优选至少约1分钟,同时保持温度高于其Tg; 和(c)在保持升高的压力的同时将聚合物冷却至Tg以下。 与可逆的许多现有技术的过渡过程不同,该方法提供可在环境条件下保持多年的液晶状态。 在优选的实施方案中,塑料是可生物腐蚀的热塑性聚合物,例如聚酐,一些聚酯,聚酰胺和多芳族化合物。 液晶聚合物可用于控制或保留包封在聚合物中的物质。 聚合物可以是各种形式,包括膜,膜层压剂和微粒。 在优选的实施方案中,LC聚合物用于包封用于医疗或药物应用的治疗剂,诊断剂或预防剂。
    • 6. 发明授权
    • Bioadhesive microspheres and their use as drug delivery and imaging systems
    • 生物粘附微球及其作为药物递送和成像系统的用途
    • US06365187B2
    • 2002-04-02
    • US09773229
    • 2001-01-31
    • Edith MathiowitzDonald E. Chickering, IIIJules Serge Jacob
    • Edith MathiowitzDonald E. Chickering, IIIJules Serge Jacob
    • A61K914
    • A61K9/1641A61K9/167Y10S514/962Y10S977/906Y10S977/915Y10S977/928
    • Bioadhesive polymers in the form of, or as a coating on, microcapsules containing drugs or bioactive substances which may serve for therapeutic, or diagnostic purposes in diseases of the gastrointestinal tract, are described. The polymeric microspheres all have a bioadhesive force of at least 11 mN/cm2 (110 N/m2) Techniques for the fabrication of bioadhesive microspheres, as well as a method for measuring bioadhesive forces between microspheres and selected segments of the gastrointestinal tract in vitro are also described. This quantitative method provides a means to establish a correlation between the chemical nature, the surface morphology and the dimensions of drug-loaded microspheres on one hand and bioadhesive forces on the other, allowing the screening of the most promising materials from a relatively large group of natural and synthetic polymers which, from theoretical consideration, should be used for making bioadhesive microspheres.
    • 描述了可以用作胃肠道疾病中的治疗或诊断目的的药物或生物活性物质的形式或作为包衣形式的生物粘附聚合物。 聚合物微球全部具有至少11mN / cm 2(110N / m 2)的生物附着力。用于制造生物粘附性微球的技术以及用于测量微球和体外胃肠道选定区段之间的生物粘附力的方法是 也描述。 这种定量方法提供了一种手段来建立化学性质,表面形态和药物负载微球的尺寸与生物粘附力之间的相关性,另一方面可以从相对较大的组中筛选出最有希望的材料 天然和合成的聚合物,从理论上考虑,应用于制造生物粘附微球。
    • 8. 发明申请
    • MONITORING OR FEEDBACK SYSTEMS AND METHODS
    • 监控或反馈系统和方法
    • US20110181410A1
    • 2011-07-28
    • US13016575
    • 2011-01-28
    • Douglas A. LevinsonHoward BernsteinDonald E. Chickering, III
    • Douglas A. LevinsonHoward BernsteinDonald E. Chickering, III
    • G08B21/00
    • G06F19/3456G06F19/00Y02A90/26
    • The present invention generally relates to systems and methods for monitoring and/or providing feedback for drugs or other pharmaceuticals taken by a subject. In one aspect, the present invention is directed to devices and methods for determining a species within the skin of a subject; and producing feedback to a subject based on the determination of the species. The feedback may be, for example, visual, audible, tactile, a change in temperature, etc. In some cases, information regarding the determination of the species may be transmitted to another entity, e.g., a health care provider, a computer, a relative, etc., which may then provide feedback to the subject in some fashion. In some cases, the feedback may be directly indicative of the species, e.g., whether the species is present, the concentration of the species, whether a by-product of a reaction involving the species is present, whether a compound affected by the species is present, etc. However, the feedback may also be indirect in some embodiments. For example, the subject may be presented with an external reward, e.g., based on the determination of the species within the skin. For instance, a reward such as cash, coupons, songs, discounts, personal items, etc., may be offered based on the level of compliance of the subject. Still other aspects of the invention are generally directed to kits involving such devices (with or without the drug to be monitored), methods of promoting such systems, or the like.
    • 本发明一般涉及用于监测和/或提供受试者所采取的药物或其他药物的反馈的系统和方法。 一方面,本发明涉及用于确定受试者皮肤内物种的装置和方法; 并根据物种的确定向对象产生反馈。 反馈可以是例如视觉,听觉,触觉,温度变化等。在一些情况下,关于物种的确定的信息可以被传输到另一个实体,例如医疗保健提供者,计算机, 相对等,其然后可以以某种方式向受试者提供反馈。 在一些情况下,反馈可以直接指示物种,例如物种是否存在,物种的浓度,是否存在涉及物种的反应的副产物,受物种影响的化合物是否为 存在等。然而,在一些实施例中,反馈也可以是间接的。 例如,受试者可以例如基于皮肤内物种的确定来呈现外部奖励。 例如,可以基于主体的合规级别来提供诸如现金,优惠券,歌曲,折扣,个人物品等的奖励。 本发明的其它方面通常涉及涉及这种装置的试剂盒(有或没有待监测的药物),促进这种系统的方法等。
    • 10. 再颁专利
    • Porous paclitaxel matrices and methods of manufacture thereof
    • 多孔紫杉醇基质及其制备方法
    • USRE40493E1
    • 2008-09-09
    • US11213257
    • 2005-08-26
    • Julie A. StraubHoward BernsteinDonald E. Chickering, IIISarwat KhattakGreg Randall
    • Julie A. StraubHoward BernsteinDonald E. Chickering, IIISarwat KhattakGreg Randall
    • A61K9/14A61K9/70A61F2/00
    • A61K9/1623A61K9/1611A61K9/1635A61K9/1694Y10S977/906
    • Paclitaxel is provided in a porous matrix form, which allows the drug to be formulated without Cremophor and administered as a bolus. The paclitaxel matrices preferably are made using a process that includes (i) dissolving paclitaxel in a volatile solvent to form a paclitaxel solution, (ii) combining at least one pore forming agent with the paclitaxel solution to form an emulsion, suspension, or second solution, and (iii) removing the volatile solvent and pore forming agent from the emulsion, suspension, or second solution to yield the porous matrix of paclitaxel. The pore forming agent can be either a volatile liquid that is immiscible with the paclitaxel solvent or a volatile solid compound, preferably a volatile salt. In a preferred embodiment, spray drying is used to remove the solvents and the pore forming agent. In a preferred embodiment, microparticles of the porous paclitaxel matrix are reconstituted with an aqueous medium and administered parenterally, or processed using standard techniques into tablets or capsules for oral administration.
    • 紫杉醇以多孔基质形式提供,其允许药物在没有Cremophor的情况下配制并作为大剂量给药。 紫杉醇基质优选使用包括(i)将紫杉醇溶解在挥发性溶剂中以形成紫杉醇溶液的方法制备,(ii)将至少一种成孔剂与紫杉醇溶液组合以形成乳液,悬浮液或第二溶液 ,和(iii)从乳液,悬浮液或第二溶液中除去挥发性溶剂和成孔剂以产生紫杉醇的多孔基质。 成孔剂可以是与紫杉醇溶剂或挥发性固体化合物,优选挥发性盐不混溶的挥发性液体。 在优选的实施方案中,使用喷雾干燥来除去溶剂和成孔剂。 在优选的实施方案中,多孔紫杉醇基质的微粒用水性介质重新配制,并肠胃外给药,或使用标准技术加工成用于口服给药的片剂或胶囊。